Destiny Pharma awarded £1.6m under new UK-China AMR programme

Funding awarded in fight against antibiotic resistance
Credit: Becky Stares

Destiny Pharma has been awarded £1.6 million via a new UK-China AMR grant fund to research novel antimicrobial candidates.

The grant has been set-up by Innovate UK and the Department of Health and Social Care with the Chinese Ministry of Science and Technology.

The two-year project will examine the use of the company’s novel XF drugs to prevent, control and eradicate life threatening bacteria or “superbugs” without generating resistance.

The research work will be carried out by Destiny Pharma’s team in collaboration with expert groups at Cardiff University’s School of Dentistry and College of Biomedical and Life Sciences – led by Professor David Williams – and a team at Tianjin Medical University, China.

Neil Clark, Destiny Pharma CEO, said: “These newly awarded funds, under the new UK‑China collaboration, will help further explore our XF drug platform in collaboration with expert teams at Cardiff University and Tianjin Medical University.

“The research will investigate the utility of our XF drug platform, especially in the treatment of dermal and ocular infections. We are hopeful this collaboration may help us identify additional clinical candidates that are safe, effective and with a significantly reduced level of antimicrobial resistance.

“Destiny Pharma is planning to complete Phase 2 trials in its lead XF programme, XF-73, in 2019 and is looking forward to identifying additional, novel drug candidates through this exciting UK-China collaboration. Destiny Pharma already has a China regional collaboration with our investor, China Medical Systems, and we are delighted to expand our strong connections in this significant market.”

Destiny Pharma’s XF-drugs have already shown great potential to address antimicrobial resistance and combat bacterial biofilms in a range of bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).

The company is due to commence a key Phase 2b study for XF-73, its lead asset, in 2019 for the prevention of for the prevention of post-surgical staphylococcal infections.